Reproductive Counseling and Dose Management in IDH-Mutant Glioma

Given the young patient population, reproductive considerations become paramount. Both male and female patients require contraception during treatment due to unknown teratogenic effects. Fertility preservation through egg or sperm harvesting represents standard counseling for patients considering vorasidenib therapy.

Dr. Cloughesy discusses tumor growth rate as a factor in reproductive planning decisions. Patients with faster tumor growth rates experience shorter PFS despite maintaining the same effect size compared to placebo. For rapidly growing tumors, he considers treatment breaks for pregnancy feasible given historical experience with watchful waiting approaches.

He doesn't believe pregnancy itself promotes tumor growth but acknowledges the theoretical possibility. Careful patient discussions can facilitate treatment holds for pregnancy completion, followed by vorasidenib resumption post-delivery.

Regarding dose modifications, liver function test elevations typically resolve with temporary holds and dose reduction from 40 mg to 20 mg. Dr. Cloughesy attempts to return patients to full dose when possible, citing perioperative study data showing inadequate 2-hydroxyglutarate inhibition at 10 mg doses.

A 20 mg dose provides uncertain efficacy compared to 40 mg, making him prefer returning to higher doses after temporary reductions. Contributing factors like alcohol consumption may allow patients to maintain full doses with lifestyle modifications. Complete resolution of liver function abnormalities before dose re-escalation remains essential.